Please provide your email address to receive an email when new articles are posted on . Growth hormone deficiency, characterized by the inadequate secretion of GH from the anterior pituitary gland, is ...

Please provide your email address to receive an email when new articles are posted on . Children with pediatric GH deficiency receiving 1.6 mg/kg per day ibutamoren orally had an annualized height ...

Growth hormone (GH) therapy has evolved rapidly since the introduction of recombinant human GH (rhGH). The increase in the availability and safety of GH therapy has also increased the number of US ...

Plasma GH levels in 11 normal children, in 5 children with hypothalamic-pituitary disorders, in 8 children with idiopathic GH deficiency and in 4 children with a constitutional growth delay were ...

Sex steroid hormones can accelerate linear growth in children with growth hormone (GH) deficiency (GHD) without GH therapy. Therefore, GHD may not be suspected in children who are in puberty. LHRH ...

A validation of the observer-reported outcome of the Growth Hormone Deficiency-Child Impact Measure found it valid and reliable to understand the impact of treatment with growth hormone therapy.

Sogroya is a long-acting form of somatropin. Somatropin is also called human growth hormone. Sogroya is made by attaching human growth hormone to a small protein that helps it stay in the body longer ...

SINGAPORE, May 29, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Australian registration of SKYTROFA® (lonapegsomatropin) as a new ...

Growth hormone treatment is a safe and effective therapy that’s often used to treat children and adults with a deficiency in human growth hormone (also known as HGH or somatropin). Naturally-occurring ...

Combined growth hormone (GH) and gonadotrophin-releasing hormone analog (GnRHa) therapy increased adult height in a cohort of "challenging-to-treat" children and teens with idiopathic short stature ...

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating ...

What Is It, and Why Does It Matter? Sogroya (somapacitan-beco) is a long-acting form of human growth hormone. You take it as a shot under the skin (subcutaneous) one time each week. It attaches to ...